- Home
- CELZ vs SONN Comparison
CELZ vs SONN Comparison
Compare CELZ & SONN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- CELZ
- SONN
- Stock Information
- Founded
- CELZ 1998
- SONN N/A
- Country
- CELZ United States
- SONN United States
- Employees
- CELZ N/A
- SONN N/A
- Industry
- CELZ Biotechnology: Pharmaceutical Preparations
- SONN Biotechnology: Pharmaceutical Preparations
- Sector
- CELZ Health Care
- SONN Health Care
- Exchange
- CELZ Nasdaq
- SONN Nasdaq
- Market Cap
- CELZ 5.5M
- SONN 4.6M
- IPO Year
- CELZ N/A
- SONN N/A
- Fundamental
- Price
- CELZ $2.02
- SONN $1.29
- Analyst Decision
- CELZ
- SONN Strong Buy
- Analyst Count
- CELZ 0
- SONN 2
- Target Price
- CELZ N/A
- SONN $38.00
- AVG Volume (30 Days)
- CELZ 34.9K
- SONN 35.6K
- Earning Date
- CELZ 05-09-2025
- SONN 05-13-2025
- Dividend Yield
- CELZ N/A
- SONN N/A
- EPS Growth
- CELZ N/A
- SONN N/A
- EPS
- CELZ N/A
- SONN N/A
- Revenue
- CELZ $14,000.00
- SONN $1,000,000.00
- Revenue This Year
- CELZ N/A
- SONN $5,376.22
- Revenue Next Year
- CELZ N/A
- SONN N/A
- P/E Ratio
- CELZ N/A
- SONN N/A
- Revenue Growth
- CELZ 55.56
- SONN 978.39
- 52 Week Low
- CELZ $1.69
- SONN $1.10
- 52 Week High
- CELZ $6.90
- SONN $16.00
- Technical
- Relative Strength Index (RSI)
- CELZ 44.81
- SONN 47.13
- Support Level
- CELZ $1.94
- SONN $1.21
- Resistance Level
- CELZ $2.20
- SONN $1.37
- Average True Range (ATR)
- CELZ 0.14
- SONN 0.07
- MACD
- CELZ 0.04
- SONN -0.01
- Stochastic Oscillator
- CELZ 40.00
- SONN 27.59
About CELZ Creative Medical Technology Holdings Inc.
Creative Medical Technology Holdings Inc is a biotechnology holding company focused on regenerative medicine. It is formed for the purpose of creating and licensing intellectual property in the area of amniotic fluid derived stem cells for therapeutic applications. Its core activity is stem cell research and the development of applications for use to treat male and female sexual dysfunction, infertility, miscarriages, and related issues.
About SONN Sonnet BioTherapeutics Holdings Inc.
Sonnet BioTherapeutics Holdings Inc is a clinical-stage biotechnology company. The Company views its operations and manages its business in one segment. The company has developed FHAB (Fully Human Albumin Binding) technology which is well suited for drug development across a range of human disease areas, including in oncology, autoimmune, pathogenic, inflammatory, and hematological conditions. The firm's pipeline products include SON-080 (low-dose IL-6), SON-1210 (IL15- FHAB-IL12), SON-1010 (IL12-FHAB), and others.